NASDAQ:CERT Certara Q2 2026 Earnings Report $6.77 -0.02 (-0.29%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$6.77 0.00 (0.00%) As of 07/10/2026 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Certara EPS ResultsActual EPSN/AConsensus EPS $0.10Beat/MissN/AOne Year Ago EPSN/ACertara Revenue ResultsActual RevenueN/AExpected Revenue$98.25 millionBeat/MissN/AYoY Revenue GrowthN/ACertara Announcement DetailsQuarterQ2 2026Date8/5/2026TimeBefore Market OpensConference Call DateWednesday, August 5, 2026Conference Call Time5:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Certara Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERTJuly 9 at 5:39 PM | prnewswire.comAI Chips Today - Certara-NVIDIA Partnership Revolutionizes AI in Drug DevelopmentJuly 8, 2026 | uk.finance.yahoo.comElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon Musk has been quietly doubling down on it, even attempting to deploy it during his time at DOGE before being shut down. Investing legend Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - has spent six years analyzing this sector he calls 'W.T.E.' He believes it could be 90 times bigger than AI and 1,900 times bigger than Bitcoin.July 12 at 1:00 AM | Brownstone Research (Ad)Certara teams up with Nvidia to strengthen AI platform with BioNeMo toolkit (CERT)July 7, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERTJuly 7, 2026 | globenewswire.comCertara, Silo Pharma Advance AI Agent Strategies with Nvidia InitiativesJuly 7, 2026 | benzinga.comSee More Certara Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Certara? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Certara and other key companies, straight to your email. Email Address About CertaraCertara (NASDAQ:CERT) is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle. The company’s offerings are divided into software tools and consulting services. Its software suite includes Phoenix WinNonlin for population pharmacokinetics and pharmacodynamics analysis, the Simcyp Simulator for physiologically based pharmacokinetic (PBPK) modeling, and the Cognigen clinical pharmacology services platform. On the services side, Certara provides regulatory strategy support, model-informed drug development (MIDD) consulting, real-world data analytics and bespoke simulation projects. These capabilities enable sponsors to address regulatory requirements, design efficient clinical trials and generate compelling evidence for product safety and efficacy. Founded in 1993 as Pharsight and later rebranded Certara in 2014, the company has grown through organic innovation and strategic acquisitions to establish a global footprint. Headquartered in Princeton, New Jersey, Certara maintains offices and development centers across North America, Europe and the Asia Pacific region. The firm is led by a management team with deep expertise in pharmacometrics, regulatory science and technology innovation, supporting a diverse client base that ranges from emerging biotech firms to large multinational pharmaceutical companies.View Certara ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels GrowthPepsiCo’s Dividend Could Turn Patience Into Real Profit Upcoming Earnings Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
